Doximity (DOCS) - 63.77% Below 52-Week High: Buy or Wait?

Stock Details

Doximity Inc (DOCS), a prominent company in the healthcare sector within the health information services industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $27.72. Over the past 52 weeks, it has ranged between $17.15 and $76.51. This places the current price at 36.2% of its 52-week high and 61.6% above its 52-week low. Recent trading volume was recorded at 65,291,122. The 14-day Relative Strength Index (RSI) stands at 74.13, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $21.28 by 30.26%. Similarly, it is below its 200-day moving average of $32.38 by 14.39%. The MACD histogram is 0.38, indicating bullish momentum (MACD Line: 0.46, Signal Line: 0.08).

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

21.08

Near market average

Forward P/E

14.62

Earnings expected to grow

PEG Ratio

0.59

Potentially undervalued

Price to Book

4.01

EV/EBITDA

13.41

EPS (TTM)

$1.30

Price to Sales

7.57

Beta

1.21

Similar volatility to market

Q:How is DOCS valued relative to its earnings and growth?

Doximity Inc trades at a P/E ratio of 21.08, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 14.62 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.59 suggests the stock may be undervalued relative to its growth rate.

Q:What is DOCS's risk profile compared to the market?

With a beta of 1.21, Doximity Inc is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 4.01 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

30.40%

Operating Margin

21.60%

EBITDA

$228.79M

Return on Equity

19.30%

Return on Assets

11.60%

Revenue Growth (YoY)

5.10%

Earnings Growth (YoY)

-69.00%

Q:How profitable and efficient is DOCS's business model?

Doximity Inc achieves a profit margin of 30.40%, meaning it retains $30.40 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 21.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 19.30% and ROA at 11.60%, the company generates strong returns on invested capital.

Q:What are DOCS's recent growth trends?

Doximity Inc's revenue grew by 5.10% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 69.00% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against HEALTH INFORMATION SERVICES industry averages for proper context.

Company Size & Market

Market Cap

$4.9B

Revenue (TTM)

$644.86M

Revenue/Share (TTM)

$3.45

Shares Outstanding

127.35M

Book Value/Share

$5.19

Asset Type

Common Stock

Q:What is DOCS's market capitalization and position?

Doximity Inc has a market capitalization of $4.9B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 127.35M shares outstanding, the company's ownership is relatively concentrated. As a participant in the HEALTH INFORMATION SERVICES industry, it competes with other firms in this sector.

Q:How does DOCS's price compare to its book value?

Doximity Inc's book value per share is $5.19, while the current stock price is $27.72, resulting in a price-to-book (P/B) ratio of 5.34. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$24.89

10.21% downside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for DOCS?

21 analysts cover DOCS with 43% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $24.89 implies -10.2% downside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on DOCS?

Current analyst recommendations:5 Strong Buy, 4 Buy, 11 Hold, 01 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 9, 2026, 02:28 AM

Technical Indicators

RSI (14-day)

74.13

Overbought

50-Day Moving Average

$21.28

30.26% above MA-50

200-Day Moving Average

$32.38

-14.39% below MA-200

MACD Line

0.46

MACD Signal

0.08

MACD Histogram

0.38

Bullish

Q:What does DOCS's RSI value tell investors?

The RSI (Relative Strength Index) for DOCS is currently 74.13, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

Q:How should traders interpret DOCS's MACD and moving average crossovers?

MACD analysis shows the MACD line at 0.46 above the signal line at 0.08, with histogram at 0.38. This bullish crossover suggests upward momentum is building. The 50-day MA ($21.28) is below the 200-day MA ($32.38), forming a death cross pattern that often warns of extended weakness. Price is currently between the MAs, suggesting transition.

Indicators last updated: Aug 9, 2026, 12:37 AM

Doximity Inc (DOCS) Stock